dromlakhani Select antidiabetic with weight‑loss benefit for T2DM overweight/obese
STEP 1 — Gather Information
Document BMI, confirm T2DM diagnosis, current metformin use, assess contraindications to GLP‑1 or SGLT‑2 inhibitors, and record HbA1c and weight‑loss goal.
STEP 2 — Rule In / Rule Out
Is metformin being used and tolerated without contraindication? If yes → proceed to Step 3. If no → Decision: Initiate metformin if not contraindicated; if metformin contraindicated, note that a GLP‑1 agonist or SGLT‑2 inhibitor may be considered as first‑line agents for weight loss and glycemic control.
STEP 3 — Classify or Stratify
Choose a GLP‑1 agonist if the patient needs greater weight loss (>5% target), has atherosclerotic cardiovascular disease, or prefers an injectable; choose an SGLT‑2 inhibitor if the patient has heart failure, chronic kidney disease, or prefers an oral medication; consider cost and side‑effect profile.
STEP 4 — Decide
Prescribe the selected agent (GLP‑1 agonist or SGLT‑2 inhibitor) in addition to metformin, titrate to effective dose, and schedule follow‑up in 4–6 weeks to assess weight change, HbA1c, and tolerability.
Clinical Guardrails / Mimics / Pitfalls
Avoid GLP‑1 agonists in patients with personal/family history of medullary thyroid carcinoma or MEN2, or history of pancreatitis; avoid SGLT‑2 inhibitors in patients with eGFR <30 mL/min/1.73 m², recurrent genital infections, hypotension, or history of ketoacidosis; do not rely on insulin for weight loss unless glycemic control necessitates it; avoid sulfonylureas, thiazolidinediones, or insulin alone when weight loss is a primary goal.
Concrete Clinical Example
A 58‑year‑old man with T2DM, BMI 32 kg/m², on metformin 1000 mg BID, HbA1c 8.0%, no contraindications, seeks weight loss. Decision: Add liraglutide 0.6 mg SC daily, increase by 0.6 mg weekly to 3.0 mg daily; reassess in 1 month.
Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415